Navigation Links
Angioslide Closes US$8.6million Series C Financing
Date:6/2/2008

HERZLIYA, Israel, June 2 /PRNewswire/ -- Angioslide, Ltd. today announced the closing of an US$8.6 million Series C financing round. Angioslide is the developer of the unique Angioslide eXtra(TM) angioplasty balloon catheter that provides dual functionality in a single device offering balloon angioplasty with embolic protection. The device has received European CE Mark approval for lower limb use and FDA clearance is expected by end of 2008. The financing will be used to support sales and marketing efforts in the U.S. and Europe as well as for continuous development of expanded market applications. European sales activities shall commence September 2008.

Itochu Corporation, Japan, led this second round of financing with support from Ofer Hi-Tech, Israel and Viola Partners, Israel, who both participated in the previous financing round.

The Angioslide eXtra balloon angioplasty catheter offers balloon angioplasty with embolic particle capture creating a first of its kind device. When performing Angioplasty physicians typically take a two-step approach using both an embolic protection device and a balloon angioplasty catheter. The Angioslide eXtra takes this two-step, two-device process and reduces it to one single instrument, used for one single procedure, with a minimized procedure time and significantly reduced costs.

"After 30 years of balloon angioplasty, this is the first time that a balloon can do more than standard inflation and deflation and the response from the medical community has been remarkable. Imagine a lower limb angioplasty product that functions as both a balloon catheter and an embolic protection device," said Doron Besser, CEO of Angioslide. "With the increasing amount of procedures being performed in the lower limbs and other peripheral regions causing a higher rate of embolic events, it is clear from capitol infusion we have received that the Angioslide eXtra is addressing an unmet need. I can't think of a better qualified investor group to partner with than, Itochu, Ofer Hi-tech and Viola, as we look to FDA approval later this year and initiating European and U.S. sales."

"We are very proud of the first involvement with the Itochu Corporation. The strong management team coupled with an innovative product offering promises to change the landscape of angioplasty and peripheral vascular disease treatment," said Lihu Avitov, Executive Vice President, Ofer Hi-Tech.

About Angioslide, Ltd. Angioslide was founded in 2005 in Herzliya, Israel. They have developed a unique angioplasty balloon catheter that has dual functionality in a single device: balloon angioplasty with embolic protection. The Angioslide eXtra addresses an unmet need for an easy-to-use, efficient and cost-effective embolic protection solution for the peripheral vascular disease market. It is the first device of its kind to seek FDA clearance for use in lower limbs. The device has received European CE Mark approval for lower limb use with FDA clearance expected by end of year 2008 followed by application for renal use. For more information contact Doron Besser at doronb@angioslide.com.

Contact:

Doron Besser

+972-9-955-6500

doronb@angioslide.com


'/>"/>
SOURCE Angioslide Ltd.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. 2008 Bank of America Chicago Marathon Registration Closes as Race Reaches 45,000 Participant Capacity
2. Health Plan One Closes $6.5 Million Series A Financing
3. MM2 Group Closes Sale for New Venture in China
4. Haemacure Discloses Positive Results of a preclinical study of its fibrin sealant in adhesion prevention and opens a new opportunity in a market with a significant unmet medical need
5. China Sky One Medical, Inc. Closes Acquisition of Heilongjiang Tianlong Pharmaceutical, Inc.
6. Breathe Technologies, Inc. Closes on $15 Million in Venture Funding Led by Kleiner Perkins Caufield & Byers
7. Alimera Sciences Closes $30 Million in Series C Financing, Increasing Stake in Medidur(TM) FA
8. Allegro Diagnostics Closes $4 Million Round to Develop and Commercialize Lung Cancer Molecular Diagnostics Based on Gene Expression
9. Providence Service Corporation to Report Fourth Quarter 2007 Results on Wednesday, March 12th After the Market Closes
10. DATATRAK Closes Second Multi-Year Enterprise Agreement with European Clinical Trial Sponsor
11. Bacterial toxin closes gate on immune response, Penn researchers discover
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... ... June 27, 2016 , ... A revolution is underway. ... transport experience for the millions of people who require these medical transport services ... industry through the use of technology. Now, SmartEMS has put forth an industry-changing ...
(Date:6/26/2016)... North Carolina (PRWEB) , ... June 26, 2016 , ... ... release of a new product that was developed to enhance the health of felines. ... for centuries. , The two main herbs in the PawPaws Cat Kidney Support ...
(Date:6/25/2016)... ... 2016 , ... The temporary closing of Bruton Memorial Library on June 21 due to a ... new, often overlooked aspect of head lice: the parasite’s ability to live away from a ... occurrence, but a necessary one in the event that lice have simply gotten out of ...
(Date:6/25/2016)... ... June 25, 2016 , ... On Friday, June 10, ... Bronze Wellness at Work award to iHire in recognition of their exemplary accomplishments in ... the 7th annual Maryland Workplace Health & Wellness Symposium at the BWI Marriott in ...
(Date:6/24/2016)... ... June 24, 2016 , ... Marcy was in a crisis. Her son James, eight, was out ... family verbally and physically. , “When something upset him, he couldn’t control his emotions,” remembers ... would throw rocks at my other children and say he was going to kill them. ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... -- , , , WHEN: , ... , , , LOCATION: , , , Online, with free ... EXPERT PANELISTS:  , , , Frost & Sullivan,s Global Vice President ... Industry Analyst, Divyaa Ravishankar and Unmesh Lal, Program Manager , ... is witnessing an exceptional era. Several new demand spaces, such as ...
(Date:6/23/2016)... , June 23, 2016  Guerbet announced today that ... Supplier Horizon Award . One of ... was recognized for its support of Premier members through ... clinical excellence, and commitment to lower costs. ... this recognition of our outstanding customer service from Premier," ...
(Date:6/23/2016)... NEW YORK , June 23, 2016 ... rough waters, but it continues to present great opportunities ... featured companies for today: Intrexon Corp. (NYSE: ... ), Arena Pharmaceuticals Inc. (NASDAQ: ARNA ), ... Learn more about these stocks and receive your complimentary ...
Breaking Medicine Technology: